CancerFree KIDS’ Post

Mirai Bio President and COO, Jens H. Vogel, Ph.D. captures the scalability challenges facing #celltherapies in this Cell & Gene Therapy Insights article, exploring innovative solutions like in vivo engineering to expand patient access and streamline production.

#FlagshipFounded Mirai Bio President & COO Jens H. Vogel, Ph.D. describes current and future innovations that aim to realize the full potential of cell and gene therapies for the benefit of patients globally in this Cell & Gene Therapy Insights article: https://lnkd.in/eWxQRu-8

While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it, such as through “off-the-shelf” options or by using different types of immune cells. Explore the current market for cancer cell therapies and what biotechs are working on next. https://lnkd.in/dR-ntd3m

Our highly anticipated cell therapy webinar is just one week away, so secure your spot before it's too late ⏳ https://ter.li/9bwzoc Get ready to explore how allogeneic cell therapies are making waves with scalable and innovative alternatives to traditional autologous treatments. Here’s a sneak peek: 💸 Total deal value involving allogeneic cell therapies in 2023 was $981 million, but this year we’ve already surpassed that investment! 🔬 130 allogeneic trials have their end dates this year, providing a wealth of new data and insights. 🧪 Over 440 allogeneic trials are currently recruiting participants. Find out more about these promising developments. Our expert panel will dive deep into these exciting advancements. Don’t miss the chance to stay ahead of the curve and unlock the potential of cutting-edge allogeneic solutions in oncology and beyond. #CellTherapy #Allogeneic #AllogeneicTherapies #MarketInsights Hanson Wade Intelligence

"Singapore has recently seen a biotech resurgence in the form of cell therapy and cell science-related start-ups." "This resurgence is undoubtedly inspired in large part by recent clinical successes using T-cell immunotherapy and associated technologies, particularly in the treatment of cancers and autoimmune diseases." -> https://shorturl.at/1Ho3P #CarTcells #cartcelltherapy #cancertherapy #biotechstocks #biotech #undervalued #immunotherapy #nasdaq #nasdaqstocks #preclinical #gdtc #investing

Leveraging living human cells to fight disease has already proven to be incredibly powerful in hematological oncology and holds huge promise, e.g. in devastating autoimmune diseases. However, autologous cell therapies are difficult to make, and 7 years after the first approvals, only about 35,000 patients have been treated with all approved products combined. We need truly breakthrough innovations to bring such therapies to all patients in need. What if.. we build targeted platforms to better engineer cells directly in vivo - skipping ex vivo cell manufacturing alltogether?! Read my short viewpoint article summarizing my thoughts. https://lnkd.in/gnZGpzvB

In general, #oncology clinical trials — and cell therapy trials in particular — are complex undertakings that present significant regulatory, operational and patient recruitment challenges to drug developers. And for the patients who participate in these trials, the therapies under investigation could perhaps be a last hope. With potentially life-saving therapies at stake, time is of the essence. Learn more from this new white paper, which outlines operational strategies that can accelerate timelines, mitigate risks, reduce patient burden and achieve success with complex protocols, more safely and efficiently. » https://bit.ly/3WAcKQg #oncologyclinicalresearch #clinicaltrials #celltherapy #drugdevelopers

While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it, such as through “off-the-shelf” options or by using different types of immune cells. Explore the current market for cancer cell therapies and what biotechs are working on next. https://lnkd.in/g2M8ueiX

While uptake has been limited, cell therapy’s impact in cancer care is growing, and biotech companies have continued to invest in ways to improve it, such as through “off-the-shelf” options or by using different types of immune cells. Explore the current market for cancer cell therapies and what biotechs are working on next. https://lnkd.in/gYyYxWyH

BeiGene: Charting New Frontiers of Affordable Cancer Cell Therapy with iPSC Derived Allogeneic CAR T BeiGene is focusing on rapidly progressing iPSC-derived cell therapy to create more effective and accessible treatments. Their strategy centers on developing homogeneous effector cell therapeutics that arise from a single, well-characterized GMP-grade iPSC clone that harbors multiple gene edits to enhance potency and longevity. Along with their proprietary differentiation and expansion methodologies, BeiGene attempts to overcome the insufficiencies of the traditional autologous and donor-based cell therapies. Watch more at  👉🏻  https://lnkd.in/gBh4aaGm #BeiGene #CellTherapy #iPSC #GeneEditing #BiotechInnovation #EffectorCells #GMP #CellTherapeutics #Biopharma #RegenerativeMedicine #HealthcareInnovation #Biotechnology #Therapeutics #PrecisionMedicine